Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591727 | 0.86 | KDM4E (0.70) | LTA4HKDM4EALDH1A1SIGMAR1CYP2D6 | |
| SCHEMBL2925566 | 0.82 | SIGMAR1 (0.60) | LTA4HKDM4EALDH1A1SIGMAR1LMNA | |
| SCHEMBL16582078 | 0.82 | ALDH1A1 (0.64) | LTA4HKDM4EALDH1A1SIGMAR1LMNA | |
| Dimethylformamide SCHEMBL27717638 | 0.81 | KDM4E (0.54) | LTA4HKDM4EALDH1A1SIGMAR1LMNA | |
| SCHEMBL7851403 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1SIGMAR1LMNA | |
| SCHEMBL3156422 | 0.78 | KDM4E (0.73) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL3280264 | 0.78 | GFER (0.51) | KDM4EALDH1A1LMNAL3MBTL1POLB | |
| SCHEMBL4260843 | 0.77 | LMNA (0.57) | LTA4HKDM4EALDH1A1SIGMAR1LMNA | |
| Sulfuric Acid SCHEMBL11839101 | 0.77 | SIGMAR1 (0.55) | LTA4HKDM4EALDH1A1SIGMAR1LMNA | |
| SCHEMBL12009956 | 0.77 | KDM4E (0.64) | LTA4HKDM4EALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | LTA4H 1868/4885KDM4E 1313/4885ALDH1A1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.